Physician profile
Suraj Singh
NPI 1962504704
$133,979.18
in general payments reported to CMS, 2019-2025
21 companies · $11K in 2025
The $11K reported for 2025 was more than what 97% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $71.78 · 2021: $593 · 2022: $1,547 · 2023: $106K · 2024: $15K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $98K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $10K · Food and Beverage: $4,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $97,747.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,112.50 |
| Travel and Lodging | $10,294.24 |
| Food and Beverage | $4,410.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Palette Life Sciences, INC. | $103,669.04 | 2022-2023 | |
| Teleflex LLC | $24,784.74 | 2024-2025 | Barrigel, Urolift |
| Emd Serono, INC. | $3,420.00 | 2023 | |
| Gt Medical Technologies, INC | $538.97 | 2021 | |
| Siemens Medical Solutions USA, INC. | $264.72 | 2022-2025 | Truebeam, Edge |
| Astrazeneca Pharmaceuticals LP | $235.55 | 2023-2024 | Imfinzi, Tagrisso |
| Merck Sharp & Dohme LLC | $140.46 | 2023-2024 | Keytruda |
| Telix Pharmaceuticals | $136.26 | 2024 | Illuccix |
| Astellas Pharma US INC | $124.98 | 2019 | |
| Sumitomo Pharma America, INC. | $119.95 | 2023-2025 | Orgovyx |
| Boston Scientific Corporation | $116.13 | 2019-2020 | |
| Novocure INC. | $65.11 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $64.26 | 2023 | Opdualag |
| Bioprotect Medical, INC. | $62.66 | 2025 | Bioprotect Balloon Implant System |
| Progenics Pharmaceuticals, INC. | $60.99 | 2023 | Pylarify |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viewray Technologies INC | $43.50 | 2022 | |
| Mim Software INC. | $41.00 | 2024 | Maestro |
| Exelixis INC. | $26.21 | 2023 | Cabometyx |
| Myovant Sciences INC. | $22.87 | 2022 | |
| Glaxosmithkline, LLC. | $22.77 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.01 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suraj Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.